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Göran K. Hansson, MD, PHDSEE PAGE 1175T he human organism possesses an immensecapacity to handle a broad variety of chal-lenges. Its cardiovascular system can switch
rapidly from maintaining basal organ perfusion in a
sedentary position to supplying hard-working mus-
cles with large amounts of oxygen during exercise.
Its neurometabolic control system is able to maintain
an even body temperature of 98.6F/37C irrespective
of whether a patient is exposed to the heat of an
Italian summer or the cold of a winter day in Sweden.
The concept of an inner milieu that remains rather
constant, thanks to counterbalancing activities, was
ﬁrst formulated 150 years ago by Claude Bernard,
the great French physiologist (1). It was summarized
in the word homeostasis and represents a central prin-
ciple in life.
In the immune system, homeostasis is obtained by
counterbalancing “killer” activities, such as cytotox-
icity and inﬂammation, with immunosuppressive
ones. This counterbalance is largely accomplished by
different subsets of immune cells, such as cytotoxic
CD8þ T cells and proinﬂammatory CD4þ T cells (Th1
cells), both controlled by anti-inﬂammatory regula-
tory T (Treg) and B cells. This homeostatic control
operates in sets of antigen-speciﬁc cells; therefore,
reactivity to antigens is tonically controlled by
counterbalancing signals. An immunological chal-
lenge, such as an infection, disturbs this equilibrium.
Innate immune stimuli prompt macrophages and
dendritic cells to produce proinﬂammatory signals
that favor the development of aggressive T and Th1
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caused by a metabolic disturbance, such as choles-
terol accumulation in the artery wall (2). Similar to
other chronic inﬂammatory diseases, such as rheu-
matoid arthritis, psoriasis, and multiple sclerosis,
adaptive as well as innate immune mechanisms
operate in atherosclerosis (3). Proinﬂammatory Th1
cells and macrophages promote disease development,
whereas Treg cells and certain B cells dampen it.
Adaptive immune activation in atherosclerosis is
driven, to a signiﬁcant extent, by autoimmune re-
actions to low-density lipoprotein cholesterol and the
intracellular protein heat shock protein-60.
Much less is known about the role of immune
mechanisms in acute coronary syndromes (ACS),
although they are usually caused by atherosclerosis.
Animal models are lacking; therefore, mechanistic
studies cannot readily be performed in ACS. However,
careful clinical studies have revealed clonal expan-
sions of T cells, some of which recognize low-density
lipoprotein (4,5). T-cell effector populations are
unbalanced, with expansion of the proinﬂammatory
CD4þCD28null cell type (4) and low levels of Treg (6).
These data reﬂect a disturbed immune homeostasis
and suggest that an immune reaction plays an
important role in ACS.Some of the T-cell changes in ACS patients are
clonal, indicating antigen-speciﬁc reactions, whereas
others are general and may therefore reﬂect a general
perturbation of cellular immunity. If the latter is the
case, what level of immune homeostasis is perturbed?
This question holds great interest not only for un-
derstanding pathogenesis but also as it may help to
identify novel therapeutic targets. The paper by Flego
et al. (7) in this issue of the Journal is a useful step
forward in this research.
T cells are activated when dendritic cells present
antigen, usually in the form of peptide fragments
bound to major histocompatibility complex proteins,
FIGURE 1 Signaling Cascades That Control Activation in T Cells
Ligation of the T-cell antigen receptor (TCR) initiates a signaling cascade that involves the
kinase zeta-chain–associated protein kinase of 70 kDa (ZAP-70) and leads to immune
activation. The outcome of this activation pathway is often inﬂammation. Counter-
balancing this activity, intracellular signals, including the cyclic adenosine monophosphate
response element–binding protein (CREB), promote the expression of the cytokines,
interleukin (IL)-2 and IL-10, the latter of which is crucial for the regulatory immunity that
dampens inﬂammation. Protein tyrosine phosphatase, nonreceptor type, 22 (PTPN22)
modulates kinase cascade activities by removing phosphate groups from tyrosine residues.
Hansson J A C C V O L . 6 5 , N O . 1 2 , 2 0 1 5
T Cells in MI M A R C H 3 1 , 2 0 1 5 : 1 1 8 7 – 9
1188to adjacent T cells. When the T-cell antigen receptor
(TCR) forms an immunological synapse with the
peptide–major histocompatibility complex, an intra-
cellular signaling cascade is elicited, leading to acti-
vation of the T cell (Figure 1). Many different proteins
participate in this cascade, but the general principle is
straightforward. A number of proteins are phosphor-
ylated, one after another, starting with the intracel-
lular parts of the TCR complex. Phospholipid and
calcium signals are called into action, ultimately
leading to activation of 3 transcription factors:
nuclear factor-kappaB, nuclear factor of activated
T cells, and activator protein-1. When activated, these
transcription factors occupy speciﬁc promoter ele-
ments that initiate deoxyribonucleic acid transcrip-
tion, which, in turn, leads to the production of
cytokines, such as interleukin-2, and to cell division.
The reacting T cell proliferates to form a clone of
cells with identical TCR amplifying the capacity to
react to antigen. In parallel, activated T cells help B
cells to produce antibodies against the antigen, alsopromoting the activation of macrophages that trigger
inﬂammation and help to remove infectious agents.
The T-cell activation cascade operates irrespective
of the type of activating antigen. Therefore, reactive
T cells expand clonally in infections and auto-
immune diseases, and in response to allogeneic
transplants. The activation cascade offers several
targets for immunosuppressive therapy. Cyclosporine
and tacrolimus target immunophilins, that is,
protein-modifying enzymes that control nuclear fac-
tor of activated T-cell activation. A combination of
sirolimus and rapamycin binds to mammalian target
of rapamycin, a kinase enzyme involved in the
pathway that activates activator protein-1 and causes
cell division. The ultimate effect of all 3 drugs is to
block T-cell activation, thus preventing the develop-
ment of adaptive immunity and immunological
memory. Treatment with this group of drugs has been
successful in diseases ranging from transplant rejec-
tion and autoimmunity to vascular restenosis.
Flego et al. (7) examined the T-cell activation
cascade in patients with non-ST-segment elevation
myocardial infarction (NSTEMI) and compared it to
the situation in patients with stable angina and in
healthy controls. They observed increased expression
and activity of tyrosine-protein phosphatase, non-
receptor type, 22 (PTPN22), an enzyme that attenu-
ates signaling in the T-cell phosphorylation cascade.
Remarkably, this increase persisted a year after the
acute event, and the authors suggest that it reﬂects an
intrinsic T-cell abnormality in ACS.
PTPN22 is an interesting enzyme because genetic
variants are associated with an increased risk for
several chronic inﬂammatory diseases; it is therefore
considered an important nonhuman leukocyte anti-
gen autoimmunity gene (8). However, the ﬁnding of
increased PTPN22 is seemingly contradictory to the
increased T-cell activity and TCR phosphorylation
events in ACS patients reported here and in previous
studies (9). The ﬁne speciﬁcity of the enzyme with
regard to its attack on phosphorylated tyrosine resi-
dues in the target proteins may perhaps explain this
paradox.
NSTEMI patients also showed transiently reduced
phosphorylation of the transcription factor cyclic ad-
enosine monophosphate response element–binding
protein in NSTEMI T cells. This reduction was
associated with reduced cyclic adenosine mono-
phosphate response element–binding protein binding
to the promoters of interleukin-2 and -10, 2 cytokines
important for Treg, andwith reduced numbers of Treg.
All of these data point to a dysregulated T-cell
homeostasis in NSTEMI. The delicate homeostasis
of immune activation appears to be disturbed in
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proinﬂammatory and regulatory immune cells. Such a
situation would justify treatment of NSTEMI, and
possibly other forms of ACS, with T-cell–modulating
strategies. Experimental studies showing the beneﬁt
of immunomodulatory therapy in atherosclerosis
could provide helpful clues for this work (10,11).
However, the present study was based on small pa-
tient groups, as pointed out by the authors, and
several questions linger with regard to thephosphorylation–dephosphorylation state in the pa-
tients’ cells. Therefore, larger immunological studies
should be performed and genomic databases scruti-
nized in order to clarify the state of T-cell homeo-
stasis in ACS.
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